A Research Study of Insulin Icodec in Adults With Type 2 Diabetes
About this study
Do you have type 2 diabetes and are currently struggling to control your glucose levels?
This clinical research study is evaluating an experimental treatment for type 2 diabetics.
This study compares insulin icodec, taken once a week, with other basal insulins, taken once a day, in people with type 2 diabetes. The purpose of this study is to see how well the approved injectable weekly insulin icodec maintains blood sugar levels when compared to approved and available daily injectable basal insulins in people with type 2 diabetes. The participants will either be prescribed weekly insulin icodec or a daily basal insulin (insulin glargine, insulin detemir or insulin degludec) based on current standards for the treatment of type 2 diabetes. The study will last for about 13 months.
Would you like to take part?
As a volunteer in a research study, you’ll receive study-related medical care from the study doctor and regular follow-up of your health to monitor the effectiveness of the care you’ll receive. The results of this research will be used to find out if the investigational medication being studied will be of benefit to others struggling to manage type 2 diabetes, and whether it will be made widely available to all Canadians. Study volunteers are an important part of moving medical care forward.
Who may qualify
- Have been diagnosed with type 2 diabetes greater than or equal to (≥) 180 days prior to the day of screening
- Have been treated with any of the following non-insulin glucose-lowering medication(s) or combination regimen(s) at the time of screening:
- Metformin, Sulfonylureas, Meglitinides (glinides), dipeptidyl peptidase-4 (DPP-4) inhibitors, sodium-glucose cotransporter-2 (SGLT2) inhibitors, Thiazolidinediones, Alpha-glucosidase inhibitors, Oral combination products (for the allowed individual oral antidiabetic drugs), Oral or injectable glucagon-like peptide-1 (GLP-1) receptor agonists and Injectable dual glucose-dependent insulinotropic polypeptides (GIP) and GLP-1 receptor agonist.
- Have need of intensification with basal insulin, as indicated at the discretion of the investigator.
- Have recorded HbA1c value ≥7% within the last 90 days prior to randomization.
- Have any known or suspected hypersensitivity to study intervention(s) or related products.
- Have any previous participation in this study. Participation is defined as signed informed consent.
- Are a female who is pregnant, breast-feeding or intends to become pregnant or is of child-bearing potential and not using adequate contraceptive method.
- Have previously participated (i.e., received any study intervention) in any interventional clinical study within 90 days before screening.
- Have any disorder which in the investigator’s opinion might jeopardize your safety.
What participation may involve
- Regular visits with the study team at no cost
- Study assessments and health monitoring throughout
- Check-ins between visits
- Informed consent before anything begins — questions welcome
What participants may receive
- Study-related care from a physician-led team
- Study assessments at no cost
- Reimbursement for reasonable travel, where applicable
Where this study is enrolling
Learn more
Diabetes
Diabetes means the level of sugar, or glucose, in your blood stays too high because your body cannot make enough insulin or cannot use the insulin it makes.…
Read about this condition →
Other studies you can explore
All current studies →
RecruitingA Study of Elecoglipron in Participants With Obesity or Overweight With or Without T2DMToronto · Montreal · VictoriaCheck availability →
RecruitingA Study of Eloralintide in Participants With Obesity, or Overweight Without Type 2 DiabetesSarnia · HamiltonCheck availability →
Limited enrolmentA Study for People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular DiseaseMontreal · StouffvilleCheck availability →